These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32347114)

  • 41. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
    Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
    Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers].
    Carrasco Font C; Arias Puente A; García Sáenz MC; Villarejo Díaz-Maroto I
    Arch Soc Esp Oftalmol; 2004 Apr; 79(4):163-8. PubMed ID: 15124072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
    Javitt J; Goldberg I
    J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sedative and physiological effects of brimonidine tartrate ophthalmic solution in healthy cats.
    Ogata N; Kanda T; Kawahata M; Ichikawa T; Matsumoto Y; Morimitsu W; Nishino Y; Itoi T; Furumoto K
    Vet Anaesth Analg; 2017 Sep; 44(5):1091-1100. PubMed ID: 28865952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use.
    Maruyama Y; Ikeda Y; Yokoi N; Mori K; Kato H; Ueno M; Kinoshita S; Sotozono C
    Cornea; 2017 Dec; 36(12):1567-1569. PubMed ID: 28938378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Results of Preoperative Use of Topical Brimonidine in Strabismus Surgery.
    Ucar F; Cetinkaya S
    J Ocul Pharmacol Ther; 2021 May; 37(4):230-235. PubMed ID: 33684337
    [No Abstract]   [Full Text] [Related]  

  • 48. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.
    Cantor LB
    Expert Opin Pharmacother; 2000 May; 1(4):815-34. PubMed ID: 11249518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre.
    Kóthy P; Holló G
    Int Ophthalmol; 2020 Feb; 40(2):377-383. PubMed ID: 31650353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brimonidine .2% as a replacement for beta blockers in geriatric patients with glaucoma.
    Noecker RJ;
    Adv Ther; 2002; 19(2):91-7. PubMed ID: 12069372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of brimonidine tartrate 0.15% on scotopic pupil: controlled trial.
    Gerente VM; Biondi AC; Barbosa CP; Lottenberg CL; Paranhos A
    J Ocul Pharmacol Ther; 2007 Oct; 23(5):476-80. PubMed ID: 17900228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
    Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
    Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
    Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
    Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of topical brimonidine on visual field in glaucoma.
    Ruiz Lapuente C; Ruiz Lapuente A; Link B
    Eur J Ophthalmol; 2001; 11 Suppl 2():S67-71. PubMed ID: 11592534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
    J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
    Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
    Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma.
    Hommer A; Thygesen J; Ferreras A; Wickstrom J; Friis MM; Buchholz P; Walt JG
    Eur J Ophthalmol; 2008; 18(5):778-86. PubMed ID: 18850558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.
    Ackerman SL; Torkildsen GL; McLaurin E; Vittitow JL
    Clin Exp Optom; 2019 Mar; 102(2):131-139. PubMed ID: 30525235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic toxicity from subcutaneous brimonidine injection successfully treated with naloxone.
    Tobarran N; Kershner E; Chambers A; Cumpston KL; Wills BK
    Am J Emerg Med; 2022 Sep; 59():218.e5-218.e6. PubMed ID: 35835657
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.